Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 61

Results For "disease"

2835 News Found

Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg
Drug Approval | November 14, 2025

Alembic receives USFDA final approval for Dexlansoprazole delayed-release capsules, 30 mg and 60 mg

Dexlansoprazole delayed-release capsules are a proton pump inhibitor


Terumo BCT and Santersus partner to advance blood purification therapy for sepsis
Technology | November 14, 2025

Terumo BCT and Santersus partner to advance blood purification therapy for sepsis

Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses


Hormone therapy for menopause gets green light from FDA
News | November 14, 2025

Hormone therapy for menopause gets green light from FDA

The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature


Daiichi Sankyo launches first-in-human trial of innovative cancer therapy
Clinical Trials | November 14, 2025

Daiichi Sankyo launches first-in-human trial of innovative cancer therapy

The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events


UK MHRA finds gut microbiome research unreliable across labs
R&D | November 14, 2025

UK MHRA finds gut microbiome research unreliable across labs

False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample


Roche reports breakthrough phase III results for investigational multiple sclerosis drug
Clinical Trials | November 14, 2025

Roche reports breakthrough phase III results for investigational multiple sclerosis drug

Fenebrutinib targets cells in the immune system known as B cells and microglia


Diabetes on the rise: Over 50% of Indians show high blood sugar, reveals report
News | November 14, 2025

Diabetes on the rise: Over 50% of Indians show high blood sugar, reveals report

Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes


Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD
Biopharma | November 14, 2025

Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD

The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology


SpyGlass Pharma reports promising clinical trial results for glaucoma therapy
Biopharma | November 14, 2025

SpyGlass Pharma reports promising clinical trial results for glaucoma therapy

The data highlight sustained intraocular pressure (IOP) reduction, drop-free treatment outcomes, and strong visual performance